Abstract
Ever since the beginning of COVID-19 Pandemic, researchers from across the world have been investigating different options for the treatment of SARS-COV-2. This is critical even after two years from the start of pandemic due to different variants resulting in new waves of this virus spreading globally. In this regard, December 22 and 23rd, 2021 are landmark days, when FDA granted authorization to Pfizer’s Paxlovid and Merck’s Molnupiravir (COVID-19 Oral Antiviral products) for emergency use (EUA). The director of the FDA’s Center for Drug Evaluation and Research Patrizia Cavazzoni, M.D., described this an enormous step to tackle this global pandemic
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
